I don't think much will change by saying goodbye to the directors. I don't think anyone in Australia would have experience selling this machine (not at the $$$ LBT would be able to afford maybe)
looks like this machine will bring better solutions to pharma companies that could afford the machines out of their pockets money. Unfortunately, after following this market for a bit I believe APAS has fallen in a very grey area where it's too big for the small players and even too expensive to justify the cost to many biggers ones. There needs to be an adoption of a different sell model, and that would keep the cash coming.
my view is once pharma starts rolling, sales will come easily on that market with a 3m-6m timeline. After that LBT should focus on APAS compact to satisfy the smaller players, and with all the traction APAS sales will develop.
this is only my view, but worst case scenario we are 6 months away from knowing
LBT Price at posting:
1.0¢ Sentiment: Hold Disclosure: Held
